Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

1.070 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 Next >
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
From OKYO Pharma LTD
Via GlobeNewswire
SmallCapsDaily Interviews OKYO Pharma CEO Dr. Gary Jacob, PHD
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
By David Willey, Benzinga 
Via TheNewswire.com
OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board
World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma 
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO to Participate at Biotech Showcase
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited - Change of Auditor
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited – PDMR dealing
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
From AmbioPharm
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.